NumerixS Investment Technologies Inc lifted its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 57.0% in the 2nd quarter, Holdings Channel reports. The firm owned 17,900 shares of the biopharmaceutical company’s stock after acquiring an additional 6,500 shares during the period. NumerixS Investment Technologies Inc’s holdings in Horizon Pharma were worth $294,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently made changes to their positions in the company. Federated Investors Inc. PA increased its holdings in Horizon Pharma by 22.2% in the 2nd quarter. Federated Investors Inc. PA now owns 782,070 shares of the biopharmaceutical company’s stock worth $12,951,000 after buying an additional 142,203 shares during the period. Brown Advisory Inc. increased its holdings in Horizon Pharma by 14.0% in the 2nd quarter. Brown Advisory Inc. now owns 38,910 shares of the biopharmaceutical company’s stock worth $644,000 after buying an additional 4,767 shares during the period. Chicago Equity Partners LLC acquired a new position in Horizon Pharma in the 2nd quarter worth approximately $2,963,000. BlackRock Inc. increased its holdings in Horizon Pharma by 3.9% in the 2nd quarter. BlackRock Inc. now owns 13,451,246 shares of the biopharmaceutical company’s stock worth $222,753,000 after buying an additional 507,323 shares during the period. Finally, GAM Holding AG acquired a new position in Horizon Pharma in the 2nd quarter worth approximately $234,000. 87.26% of the stock is owned by hedge funds and other institutional investors.
In related news, EVP Geoffrey M. Curtis sold 9,904 shares of Horizon Pharma stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $20.63, for a total value of $204,319.52. Following the sale, the executive vice president now owns 28,767 shares of the company’s stock, valued at approximately $593,463.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.90% of the stock is currently owned by company insiders.
A number of equities research analysts have recently commented on the stock. BidaskClub raised shares of Horizon Pharma from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 10th. Morgan Stanley raised their price objective on shares of Horizon Pharma from $16.00 to $24.00 and gave the stock an “equal weight” rating in a research note on Friday, August 17th. Jefferies Financial Group raised their price objective on shares of Horizon Pharma from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. Mizuho reaffirmed a “buy” rating and set a $18.00 price objective on shares of Horizon Pharma in a research note on Wednesday, August 8th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $25.00 price objective on shares of Horizon Pharma in a research note on Thursday, August 9th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Horizon Pharma presently has an average rating of “Buy” and a consensus price target of $21.00.
Horizon Pharma stock opened at $20.52 on Friday. Horizon Pharma PLC has a 1 year low of $11.17 and a 1 year high of $21.25. The firm has a market capitalization of $3.49 billion, a P/E ratio of 19.76, a P/E/G ratio of 1.33 and a beta of 1.49. The company has a debt-to-equity ratio of 2.19, a quick ratio of 1.63 and a current ratio of 1.70.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.17. Horizon Pharma had a negative net margin of 28.02% and a positive return on equity of 19.05%. The firm had revenue of $302.84 million for the quarter, compared to analysts’ expectations of $275.51 million. During the same quarter last year, the company earned $0.41 EPS. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. analysts forecast that Horizon Pharma PLC will post 1.34 EPS for the current year.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Read More: How Do Tariffs Affect Trade Balances?
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.